HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Nanotech Metrics, Safety Should Trump Size, Experts Say

This article was originally published in The Tan Sheet

Executive Summary

Presenters at the FDLI annual conference say evaluations of novel health care and consumer products based on nanotechnology should focus on safety and efficacy more than particle size. The Project on Emerging Nanotechnologies is updating its product inventory to include nanomaterial safety data.

You may also be interested in...



European Nanomaterial Definition Brings Measurement Challenges

The European Commission’s definition of “nanomaterial,” to potentially be used in legislation, appears to be relatively simple. In practice, measuring particles against the standard offers a number of technological challenges.

“Nano-Free” Sunscreen Claim Spurs Environmental Group Complaint

Friends of the Earth claims that materials supplier Antaria misleads its customers and consumers by billing the ZinClear-IM sunscreen ingredient as “nano-free” when third-party testing shows it contains “clusters” of nanoparticles. The issue of defining nanotechnology continues to be debated internationally.

U.S., EU Nanotech Guidances Demonstrate “Growing Consensus” – PCPC

The Personal Care Products Council’s Jay Ansell, VP of cosmetic programs, is optimistic about the direction regulators are taking and the consensus developing among scientific experts regarding the use of nanomaterials in cosmetics. However, challenges remain for firms faced with requirements under European law, and further harmonization is needed between international regulatory regimes, he suggests.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel